NASDAQ:APOP

Cellect Biotechnology Stock Forecast, Price & News

$3.04

-0.12 (-3.80 %)

(As of 06/11/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.03

▼

$3.14

50-Day Range

$2.15

▼

$3.45

52-Week Range

$1.65

▼

$7.15

Volume63,993 shs

Average Volume352,284 shs

Market Capitalization$6.81 million

P/E RatioN/A

Dividend YieldN/A

Beta1.81

30 days | 90 days | 365 days | Advanced Chart

Receive APOP News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellect Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

About Cellect Biotechnology

Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische UniversitÃ¤t Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was incorporated in 1986 and is headquartered in Kfar Saba, Israel.

Cellect Biotechnology (NASDAQ:APOP) Stock Price Down 2.7%
June 9, 2021 | americanbankingnews.com

/R E P E A T -- Halo Collective Inc. Reports Record First Quarter Results/
May 17, 2021 | finance.yahoo.com

Halo Collective Inc. Reports Record First Quarter Results
May 17, 2021 | finance.yahoo.com

Cellect Bio's ApoGraft Therapy Is Safe, Tolerable In GvHD Study
April 19, 2021 | finance.yahoo.com

Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial
April 19, 2021 | finance.yahoo.com

Cellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
March 29, 2021 | finance.yahoo.com

Cellect Biotechnology Ltd.: Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger
March 26, 2021 | finanznachrichten.de

Cellect Jumps on Quoin Hookup
March 25, 2021 | baystreet.ca

Why Is It Moving? Looking Into Why Cellect Biotechnology's Stock is Trading Higher Today
March 25, 2021 | msn.com

Why PRQR Stock And APOP Stock Are Popping Off Today
March 25, 2021 | markets.businessinsider.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APOP
Previous Symbol
CUSIPN/A
CIK1671502
Webwww.cellect.co
Phone972-9974-1444
Employees12
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.08 per share
Price / Book1.46

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares2,240,000
Market Cap$6.81 million
Next Earnings Date6/17/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.56 out of 5 stars

Medical Sector

1507th out of 2,099 stocks

Surgical & Medical Instruments Industry

137th out of 174 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Cellect Biotechnology.

2.8 Community Rank

Outperform Votes
Cellect Biotechnology has received 349 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Cellect Biotechnology has received 264 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Cellect Biotechnology has received 56.93% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Cellect Biotechnology and other stocks. Vote “Outperform” if you believe APOP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APOP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Cellect Biotechnology does not currently pay a dividend.
Dividend Growth
Cellect Biotechnology does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cellect Biotechnology insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 8.68% of the stock of Cellect Biotechnology is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Cellect Biotechnology is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cellect Biotechnology is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cellect Biotechnology has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Cellect Biotechnology (NASDAQ:APOP) Frequently Asked Questions

What stocks does MarketBeat like better than Cellect Biotechnology?

Wall Street analysts have given Cellect Biotechnology a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cellect Biotechnology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cellect Biotechnology's next earnings date?

Cellect Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, June 17th 2021.
View our earnings forecast for Cellect Biotechnology.

How were Cellect Biotechnology's earnings last quarter?

Cellect Biotechnology Ltd. (NASDAQ:APOP) issued its earnings results on Monday, March, 29th. The company reported ($0.39) EPS for the quarter.
View Cellect Biotechnology's earnings history.

How has Cellect Biotechnology's stock price been impacted by Coronavirus?

Cellect Biotechnology's stock was trading at $1.71 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, APOP shares have increased by 77.8% and is now trading at $3.04.
View which stocks have been most impacted by COVID-19.

Who are Cellect Biotechnology's key executives?

Cellect Biotechnology's management team includes the following people:

Dr. Shai Yarkoni, Co-Founder, CEO & Director (Age 63)
Mr. Eyal Leibovitz, Chief Financial Officer (Age 60)
Dr. Amos Ofer, Chief Operating Officer (Age 45)
Dr. Yael Kenan, VP of Clinical Affairs (Age 58)

Who are some of Cellect Biotechnology's key competitors?

Some companies that are related to Cellect Biotechnology include InVivo Therapeutics (NVIV), Arch Therapeutics (ARTH), Lianluo Smart (LLIT), Ra Medical Systems (RMED), Dynatronics (DYNT), NeuroMetrix (NURO), Biostage (BSTG), Encision (ECIA), MeaTech 3D (MTTCF), H-CYTE (HCYT), Regenicin (RGIN), Safeplus International (BIPHD), Safeplus International (ACAI), CVR Medical (CRRVF) and Medite Cancer Diagnostics (MDIT).
View all of APOP's competitors.

What other stocks do shareholders of Cellect Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellect Biotechnology investors own include Elbit Systems (ESLT), Gilead Sciences (GILD), Protalix BioTherapeutics (PLX), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Acasti Pharma (ACST), Allergan (AGN), Novavax (NVAX) and RedHill Biopharma (RDHL).

What is Cellect Biotechnology's stock symbol?

Cellect Biotechnology trades on the NASDAQ under the ticker symbol "APOP."

Who are Cellect Biotechnology's major shareholders?

Cellect Biotechnology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.95%), HRT Financial LP (0.93%), Virtu Financial LLC (0.91%), Citadel Advisors LLC (0.73%) and Citadel Advisors LLC (0.73%).

Which institutional investors are selling Cellect Biotechnology stock?

APOP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

Which institutional investors are buying Cellect Biotechnology stock?

APOP stock was acquired by a variety of institutional investors in the last quarter, including HRT Financial LP, Virtu Financial LLC, Citadel Advisors LLC, and Citadel Advisors LLC.

How do I buy shares of Cellect Biotechnology?

Shares of APOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellect Biotechnology's stock price today?

One share of APOP stock can currently be purchased for approximately $3.04.

How much money does Cellect Biotechnology make?

Cellect Biotechnology has a market capitalization of $6.81 million.

How many employees does Cellect Biotechnology have?

Cellect Biotechnology employs 12 workers across the globe.

What is Cellect Biotechnology's official website?

The official website for Cellect Biotechnology is www.cellect.co.

Where are Cellect Biotechnology's headquarters?

Cellect Biotechnology is headquartered at 23 HATA`AS STREET, KFAR SABA L3, 44425.

How can I contact Cellect Biotechnology?

Cellect Biotechnology's mailing address is 23 HATA`AS STREET, KFAR SABA L3, 44425. The company can be reached via phone at 972-9974-1444 or via email at [email protected]

This page was last updated on 6/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here